Home > Press > BioForce Receives Notice of Allowance for Its 'Chip-On-A-Tip' Patent
BioForce Nanosciences Holdings Inc. (OTCBB:BFNH) announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office for its Chip-On-A-Tip(tm) patent.
BioForce Receives Notice of Allowance for Its 'Chip-On-A-Tip' Patent
AMES, IA | Posted on December 11th, 2007
Chip-On-A-Tip(tm) (COAT(tm)) is a revolutionary method for performing diagnostic tests on extremely small tissue and liquid samples. It involves placement of an ultra-miniaturized diagnostic test at the end of a device, such as a surgical probe, as a means of collecting the tiny amounts of material necessary for the ultra-miniaturized tests to provide a diagnosis. The COAT method can be applied to the diagnosis of diseases, such as cancer, and for small sample analysis, as is the case with neonates and forensics specimens.
BioForce has utilized COAT to successfully perform cancer protein biomarker screening from as few as four cells, demonstrating the detection of prostate-specific antigen (PSA), which is commonly used for the diagnosis of prostate cancer.
Dr. Eric Henderson, BioForce's CEO, said, "COAT is one example of the NanoDiagnostic testing technologies under development at BioForce. The concept behind NanoDiagnostic tests is to address the many instances where it is highly desirable to be able to obtain a diagnosis using miniscule samples in order to minimize patient invasiveness or simply because larger samples are not readily available. This is particularly important when analyzing protein biomarkers, which are indicators of disease and, unlike DNA, cannot be amplified by any known process. In order to do this, the diagnostic test itself must be of a size scale consistent with the sample size, which can be as small as a single cell. Examples of when this is important include tests involving neonatal blood, forensic specimens, and cells aspirated from a tumor."
Henderson continued, "The Notice of Allowance on the COAT patent is the third significant development in our intellectual property portfolio during 2007. Earlier this year, we received confirmation of our Protein Nanoarray patent, covering protein arrays with feature sizes of less than one micron squared for creating ultra-miniaturized diagnostic tests and micro-environments for the study of cell biology. We also received a Notice of Allowance for our Sindex(tm) chip patent. Sindex chips are indexed silicon substrates that serve as the basis for a host of ultra-miniaturized tests."
Kerry Frey, BioForce's COO, added, "Our platform technology, the Nano eNabler(tm) molecular printing system, is instrumental for the construction of ultra-miniaturized diagnostic tests, such as the COAT device. We believe that COAT is just one of many paradigm-shifting technologies that will emerge from the Nano eNabler's capabilities. Our patented ViriChip(tm) virus detection technology is a second example of products resulting from BioForce's internal use of the Nano eNabler. Additionally, we now have a significant worldwide base of customers who have purchased Nano eNablers and are using them to create an ever-expanding arsenal of forward-looking inventions in areas including health care, tissue engineering, stem cells, neurobiology, cancer cell biology and biosensors."
Frey continued, "As our business grows, we are very cognizant of the importance of continued innovation, both internally and in collaboration with our customer-colleagues. Reaching out to our customers and embracing new ideas and opportunities is a cornerstone of our business philosophy."
About BioForce Nanosciences Holdings Inc.
BioForce Nanosciences is an innovation company that develops and commercializes nanotechnology-driven tools and solutions for the life sciences. BioForce's flagship product, the Nano eNabler(tm) molecular printer, gives the Company and its customers a unique platform for development and discovery in areas such as cell biology, biosensors, and ultra-miniaturized surface modification. For more information, visit www.bioforcenano.com or call 515-233-8333.
This news release contains forward-looking information that may be affected by certain risks and uncertainties, including those risks and uncertainties described in BioForce Nanosciences' most recent filings with the Securities and Exchange Commission. BioForce Nanosciences' actual results could differ materially from such forward-looking statements. BioForce assumes no duty to update these statements at any future date.
For more information, please click here
BioForce Nanosciences Holdings, Inc.
Greg Brown, CFO
515-233-8333 ext. 118
RedChip Companies, Inc.
1-800-REDCHIP (733-2447) ext. 104
Copyright © PrimeNewswire
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Creation of 'Rocker' protein opens way for new smart molecules in medicine, other fields December 18th, 2014
Iranian Researchers Produce Electrical Pieces Usable in Human Body December 18th, 2014
Unraveling the light of fireflies December 17th, 2014
First Home-Made Edible Herbal Nanodrug Presented to Pharmacies across Iran December 17th, 2014
Atom-thick CCD could capture images: Rice University scientists develop two-dimensional, light-sensitive material December 20th, 2014
Oregon researchers glimpse pathway of sunlight to electricity: Collaboration with Lund University uses modified UO spectroscopy equipment to study 'maze' of connections in photoactive quantum dots December 19th, 2014
Instant-start computers possible with new breakthrough December 19th, 2014
Aculon Hires New Business Development Director December 19th, 2014
Silicon Valley-Based Foresight Valuation Launches STR-IP™, a New Initiative for Startups to Discover the Value of Their Intellectual Property December 18th, 2014
Chemists Fabricate Novel Rewritable Paper: An attractive alternate to regular paper, UC Riverside-developed technology helps address increasing problems in environment and resource sustainability December 2nd, 2014
Dicerna Announces License Agreement with Tekmira to Advance Dicerna’s PH1 Development Program November 17th, 2014
First genetic-based tool to detect circulating cancer cells in blood: NanoFlares light up individual cells if breast cancer biomarker is present November 17th, 2014